Literature DB >> 2908872

Combination of ketanserin and verapamil or propranolol in patients with alcoholic cirrhosis: search for an additive effect.

A Hadengue1, R Moreau, R Cerini, A Koshy, S S Lee, D Lebrec.   

Abstract

Drugs reported to reduce portal pressure through different mechanisms were combined in the hope of either additive portal hypotensive effects in "responders," or inducing a portal hypotensive effect in "nonresponders" to the initial drug. Seven patients with alcoholic cirrhosis received verapamil, 10 mg i.v., and, 60 min later, ketanserin, 5 mg i.v. Verapamil decreased heart rate and increased free hepatic venous pressure but had no effect on hepatic venous pressure gradient or azygos blood flow. When combined with verapamil, ketanserin significantly diminished wedged hepatic venous pressure and hepatic venous pressure gradient. Ten other patients with alcoholic cirrhosis received propranolol, 15 mg i.v., and 45 min later, ketanserin, 5 mg i.v. In all patients, heart rate, cardiac index and azygos blood flow significantly decreased after propranolol. After propranolol alone, however, wedged hepatic venous pressure decreased in only five patients, responders. In five other patients, defined as nonresponders, propranolol did not decrease this pressure. The addition of ketanserin to propranolol induced further significant reduction in wedged hepatic venous pressure, hepatic venous pressure gradient and azygos blood flow. Among the five nonresponders, three had a reduced wedged hepatic venous pressure after ketanserin was combined. We conclude that verapamil does not reduce portal pressure or collateral blood flow in patients with alcoholic cirrhosis. The splanchnic hemodynamic effects of propranolol and ketanserin appear to be independent and additive, without significant systemic alteration.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2908872     DOI: 10.1002/hep.1840090113

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  4 in total

1.  Effects of calcium antagonists on hepatic and systemic hemodynamics in awake portal hypertensive rats.

Authors:  M Nagasawa; T Kawasaki; T Yoshimi
Journal:  J Gastroenterol       Date:  1996-06       Impact factor: 7.527

Review 2.  Calcium antagonists. Drug interactions of clinical significance.

Authors:  T Rosenthal; D Ezra
Journal:  Drug Saf       Date:  1995-09       Impact factor: 5.606

Review 3.  Portal hypertension: serotonin and pathogenesis.

Authors:  D Lebrec
Journal:  Cardiovasc Drugs Ther       Date:  1990-01       Impact factor: 3.727

4.  Potentiation of responses to sympathetic nerve stimulation and vasoconstrictor agents by SK&F 103829 in the feline mesenteric circulation.

Authors:  E M Taylor; A J Kaumann
Journal:  Br J Pharmacol       Date:  1994-01       Impact factor: 8.739

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.